Background Influenza is associated with a high mortality and morbidity in older adults.
Vaccination remains the most effective method of preventing influenza and its …

Although vaccination against influenza is recommended for elderly and high-risk patients in
many countries, efficacy in the elderly has been suboptimal. The MF59 adjuvanted trivalent …

Adults over the age of 60‐65 years suffer disproportionally from seasonal influenza,
experiencing high rates of complications, exacerbation of underlying medical comorbidities …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

Annual vaccination is the main mean of preventing influenza in the elderly. In order to
evaluate the effectiveness of the adjuvanted seasonal influenza vaccines available in Italy in …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

To determine if newer influenza vaccines can safely improve seroprotection rates of older
adults, we compared three licensed trivalent inactivated vaccines (TIVs) in a randomized …

Background We aimed to compare AS03-adjuvanted inactivated trivalent influenza vaccine
(TIV) with non-adjuvanted TIV for seasonal influenza prevention in elderly people. Methods …

Background There is an urgent need for improved influenza vaccines especially for older
adults due to the presence of immunosenescence. It is therefore highly relevant to compare …

MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent
inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults …